BCL-X L –targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors
Andrew S. Judd, Bhupinder Bawa, Wayne R. Buck, Zhi‐Fu Tao et autres
23 citationsScience Advances
Michael J. Mitten
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
100Publications signalées
12116Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Multiple Myeloma Research and TreatmentsPeptidase Inhibition and AnalysisProtein Degradation and InhibitorsCell death mechanisms and regulationHER2/EGFR in Cancer Research
Publications récentes
Supplementary Figure 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Mark G. Anderson, Hugh D. Falls, Michael J. Mitten, Anatol Oleksijew et autres
0 citations
Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Mark G. Anderson, Hugh D. Falls, Michael J. Mitten, Anatol Oleksijew et autres
0 citations
Supplementary Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Mark G. Anderson, Hugh D. Falls, Michael J. Mitten, Anatol Oleksijew et autres
0 citations
Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Mark Anderson, Hugh D. Falls, Michael J. Mitten, Anatol Oleksijew et autres
0 citations
Data from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya, Michael J. Mitten et autres
0 citations
Data from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Figure 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Table 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Table 1 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
Supplementary Figure 3 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.